Ikerian

What Ikerian does

Ikerian AG is a Swiss-headquartered, venture-backed healthcare AI company that builds Discovery, an FDA 510(k)-cleared and EU-MDR Class IIa-certified medical image and data platform. Discovery harmonizes multimodal healthcare data — retinal imaging combined with clinical and structured data — and applies proprietary computer-vision and machine-learning models to extract biomarkers, monitor disease progression, and predict outcomes, initially in ophthalmology and now expanding into neurodegenerative, vascular, and rare disease indications.

The platform is modular: the core RetinAI Discovery product performs multimodal data harmonization and AI-based biomarker extraction, while Discovery CONNECT (scheduled for Q1 2025) automates anonymized data uploads into clinical workflows. As of the latest disclosures, Discovery has processed over 1 million patient images, supported more than 20 clinical studies, and generated 40+ peer-reviewed publications; 15 pharmaceutical and research customers are disclosed, including Novartis, Boehringer Ingelheim, Johnson & Johnson, and Topcon Healthcare.

Ikerian monetizes through enterprise subscription SaaS contracts with pharmaceutical companies, clinics, hospitals, CROs, and research institutions, supplemented by a commercial agreement with Sanoptis that provides distribution across 420+ ophthalmology clinics in six European countries. The company is led by co-founders Carlos Ciller (CEO), Stefanos Apostolopoulos (CTO), and Sandro De Zanet (CSO), all board members, with board representation from Sanoptis and Topcon Healthcare; it closed the first tranche of a Series B at USD 8M in October 2024 led by Sanoptis.

Name

Ikerian

Legal name

IKERIAN AG

Website

https://ikerian.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Ikerian AG builds Discovery, an FDA-cleared and EU-MDR-certified AI platform that analyzes multimodal healthcare data, initially retinal imaging, for pharmaceutical companies, clinics, CROs, and research institutions across Europe and North America.

Ownership category

akta.pro rank

Product category

Healthcare AI Software (Medical Imaging Analytics)

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Electronic Data Capture (EDC) Platforms (HLACAOAA)

akta.pro secondary industries

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Medical imaging analytics
• Healthcare AI software
• Ophthalmology data platform
• Clinical trial analytics
• Retinal biomarker analysis

Headquarters

HQ city

Bern

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure, Others

Revenue model

1. Discovery Platform Subscription: Discovery platform is offered as a subscription-based SaaS model for pharmaceutical companies, clinics, hospitals, CROs, and research institutions. The company describes growing sales from RetinAI Discovery indicating an active commercial stage with recurring subscription revenue.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Ikerian develops and sells RetinAI Discovery, a modular, FDA 510(k)-cleared and CE-MDR Class IIa certified healthcare software platform that uses AI and computer vision to harmonize, standardize, and analyze multimodal medical data (retinal images, clinical data, biomarkers). The platform enables pharmaceutical companies, clinics, hospitals, CROs, and research institutions to accelerate clinical trials, extract AI-based biomarkers, monitor disease progression, and automate clinical workflows, with primary focus on ophthalmology and expansion into neurodegenerative, vascular, and rare diseases.

Product overview

Ikerian offers a unified healthcare software platform called Discovery, a modular and certified (FDA 510(k) / CE-MDR) medical image and data platform. The core product RetinAI Discovery harmonizes multimodal healthcare data at scale, enabling AI-based biomarker extraction and disease progression monitoring. The platform supports four therapeutic areas: ophthalmology, neurodegenerative disorders, vascular conditions, and rare diseases. Discovery is augmented by Discovery CONNECT, a module for automated data uploads and anonymization, and proprietary AI models for retinal biomarker analysis, fluid segmentation, and layer quantification.

Differentiator

Problem solved

Functional benefit

Brands

• RetinAI Discovery: A modular, certified (FDA 510(k) / CE-MDR) medical image and data platform that harmonizes, standardizes, and analyzes multimodal healthcare data to enable evidence-based decisions. Discovery is described as the workbench for healthcare professionals enabling precision analysis with proprietary AI models.
• Discovery CONNECT

Products and services

• RetinAI Discovery A modular, FDA 510(k)-cleared and CE-MDR Class IIa certified medical image and data platform that harmonizes multimodal healthcare data (retinal images, clinical data, biomarkers) at scale and applies proprietary AI models for biomarker extraction, disease monitoring, and clinical decision support. Used by pharmaceutical companies, clinics, hospitals, CROs, and research institutions across ophthalmology and adjacent therapeutic areas.
• Discovery CONNECT A customized software solution designed to automate, anonymize, and synchronize imaging data uploads within clinical workflows and networks. Ensures sensitive health information is securely transferred with advanced anonymization techniques, supporting real-world evidence generation and optimized clinical study recruitment. Scheduled for deployment in Q1 2025.
• AI-based Retinal Biomarker Models Certified AI models that identify and quantify retinal layers, retinal fluids, and retinal biomarkers to support diagnosis and monitoring of diseases in ophthalmology. Includes fluid segmentation, layer segmentation, and quantification in retinal pathologies, certified under EU MDR Class IIa and (for the platform) FDA 510(k).

Quantifiable outcome

• Processed 1 million patient images to date
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• NovartiscoreStrategic or Co-development Partner · 1 January 2020Partnership established in 2020 for accelerating clinical trials using Discovery platform. Discovery received CE marking and partnership was secured with Novartis for clinical trial acceleration.
• Boehringer IngelheimcoreStrategic or Co-development PartnerEstablished collaboration with Boehringer Ingelheim for AI-driven healthcare solutions in ophthalmology and oculomics research.
• Johnson & Johnson (J&J)coreStrategic or Co-development PartnerEstablished collaboration with Johnson & Johnson for AI-powered healthcare solutions.
• Topcon Healthcare Inc.coreStrategic or Co-development PartnerStrategic partnership for Harmony platform integration and Healthcare from the Eye oculomics technology. Topcon Healthcare is a leading provider of eyecare solutions with a connected care ecosystem powered by their cloud-based Harmony platform.
• RetinAI Consultants of America (RCA)supportingStrategic or Co-development PartnerCollaboration with RetinAI Consultants of America for US market operations and consulting services.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Optos (Nikon Healthcare): Optos, part of Nikon Healthcare, is a retinal imaging device incumbent (ultra-widefield retinal imaging). It is comparable as a broad ophthalmic imaging incumbent whose installed base and AI roadmap overlap with Ikerian's analytics layer.
• Heidelberg Engineering: Heidelberg Engineering manufactures premium retinal imaging systems (Spectralis OCT, etc.) and increasingly bundles analytics. It is a broad incumbent in the ophthalmic imaging value chain where Ikerian's biomarker AI competes for workflow ownership.
• ZEISS Medical Technology: ZEISS Medical Technology is a global ophthalmology device and diagnostics incumbent spanning imaging, surgical, and clinical workflow solutions. Its broad portfolio overlaps with Ikerian's ophthalmology AI focus at the device-and-workflow layer.
• Topcon Healthcare: Topcon Healthcare is a leading eyecare device and connected-care platform provider (Harmony), which is simultaneously a strategic investor/partner via THINC Ventures and a potential broad incumbent whose device ecosystem competes for AI-analytics mindshare with Ikerian's Discovery.

Direct peers

• Eyenuk: Eyenuk provides FDA-cleared AI eye diagnostics, including diabetic retinopathy screening and other retinal image analytics. It competes directly with Ikerian in AI-driven ophthalmic image interpretation sold to clinics and healthcare systems.
• AEYE Health: AEYE Health develops FDA-cleared AI for autonomous retinal screening and diagnosis. It is a direct competitor in AI-powered ophthalmic imaging analysis with overlapping pharma and clinical customer use cases.
• Digital Diagnostics: Digital Diagnostics (IDx-DR) pioneered FDA-cleared autonomous AI diagnostics in ophthalmology. It is a direct peer in clinically deployed AI retinal analysis and shares Ikerian's FDA regulatory pathway approach.

Emerging players

• Arterys: Arterys (acquired by Tempus) provides cloud-native AI medical imaging analytics across multiple modalities. It is comparable to Ikerian as an emerging cloud-based medical imaging AI platform serving enterprise clinical and research customers.
• Voxeleron: Voxeleron is a smaller emerging player focused on AI-based ophthalmic image analytics, particularly OCT biomarker quantification. It is comparable to Ikerian at the biomarker-analysis layer of the ophthalmology AI stack.
• DeepHealth (RadNet): DeepHealth, a RadNet subsidiary, develops AI for medical imaging across modalities including ophthalmology. It is an emerging player whose broader imaging AI portfolio intersects with Ikerian's multimodal data harmonization and biomarker analytics capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/ikerian

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ikerian